Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00171821
Registration number
NCT00171821
Ethics application status
Date submitted
13/09/2005
Date registered
15/09/2005
Date last updated
11/02/2020
Titles & IDs
Public title
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
Query!
Scientific title
A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload
Query!
Secondary ID [1]
0
0
2004-003953-16
Query!
Secondary ID [2]
0
0
CICL670A2409
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Transfusion-dependent Iron Overload
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Other diet and nutrition disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: ICL670 (Deferasirox) -
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To evaluate if fixed starting doses of ICL670, based on transfusion history and subsequent dose titration can provide clinically acceptable chelation as measured by serum ferritin
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
at baseline and at 52 weeks
Query!
Secondary outcome [1]
0
0
To evaluate the safety and tolerability profile of in patients treated for up to 52 weeks
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Monthly
Query!
Secondary outcome [2]
0
0
Evaluate efficacy, tolerabilty and safety in the subgroup of patients with baseline LIC < 7 mg Fe/g dw
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Monthly
Query!
Secondary outcome [3]
0
0
Evaluate the relationship between serum ferritin and potential surrogate markers
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Monthly
Query!
Eligibility
Key inclusion criteria
* Patients presenting with transfusion-dependent anemias (independent of underlying condition) with transfusional iron overload as shown by a serum ferritin level of = 1000 ng/ml
* Patients of either gender and aged = 2 years
* Female patients who have reached menarche and who are sexually active must use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation.
Additional Inclusion Criteria for Adult Patients:
* Written informed consent by the patient
Additional Inclusion Criteria for Pediatric Patients:
* The definition of the term "pediatric" will be in accordance with local legislation. Parents or legal guardians will be fully informed by the investigator as to the requirements of the study. The pediatric patients themselves will be informed according to their capabilities in a language and terms that they are able to understand. Written informed consent will be obtained from their parents or legal guardians on the patient's behalf in accordance with the national legislation. If capable, all patients should also personally sign their written informed assent.
Query!
Minimum age
2
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Non-transfusional hemosiderosis
* Patients with clinical evidence supporting the need for intensive chelation, based on the investigator's judgment
* Patients with mean levels of alanine aminotransferase (ALT) > 300 U/l
* Patients with uncontrolled systemic hypertension
* Patients with serum creatinine above the upper limit of normal (ULN)
* Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 (mg/mg) in second-voiding urine samples taken at both visits 1 and 2. A third sample is to be taken from patients in whom one ratio is > 0.5 (mg/mg) and one is = 0.5 (mg/mg) and patients in whom the urinary protein/creatinine ratio is > 0.5 (mg/mg) in two of the three determinations are also to be excluded.
* History of nephrotic syndrome
* Patients with 3rd atrioventricular (A-V) block, clinically relevant Q-T interval prolongation as well as patients requiring treatment with digoxin and similar compounds or drugs which may induce prolongation of the Q-T interval
* Patients with a previous history of clinically relevant ocular toxicity related to iron chelation
* Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
* Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment
* Pregnant or breast feeding patients
* Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drugs within the past 7 days
* Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
* history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
* history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
* history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase;
* history or presence of impaired renal function as indicated by creatinine or blood urea nitrogen (BUN) values equal or above ULN;
* history of urinary obstruction or difficulty in voiding.
* History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
* History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the run-in period
* Patients with positive test to HIV
* Life expectancy of < 1 year
Exclusion Criteria for Pediatric Patients:
* Patient body weight which prevents the use of the smallest tablet strength (i.e. 125 mg) for proper dosing
Other protocol-defined inclusion/exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1784
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Camperdown
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Clayton
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Perth
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - South Brisbane
Query!
Recruitment hospital [7]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Camperdown
Query!
Recruitment postcode(s) [3]
0
0
- Clayton
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment postcode(s) [5]
0
0
- Perth
Query!
Recruitment postcode(s) [6]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [7]
0
0
- Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Graz
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Linz
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Wien
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Brussels
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Gent
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Godinne
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
La Louviere
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Leuven
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
GuangZhou
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Nanjing
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Shanghai
Query!
Country [12]
0
0
Denmark
Query!
State/province [12]
0
0
Arhus
Query!
Country [13]
0
0
Denmark
Query!
State/province [13]
0
0
Copenhagen
Query!
Country [14]
0
0
Denmark
Query!
State/province [14]
0
0
Herlev
Query!
Country [15]
0
0
Denmark
Query!
State/province [15]
0
0
Hillerod
Query!
Country [16]
0
0
Egypt
Query!
State/province [16]
0
0
Cairo
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Angers
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Avignon
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Bobigny
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Creteil
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Lille Cedex
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Lyon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Nice
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris Cedex 14
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Pessac Cedex
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Rennes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Toulouse Cedex
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Vandoeuvre Les Nancy
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Augsburg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Braunschweig
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Dresden
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Dusseldorf
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Frankfurt/Main
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Frankfurt
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Frieburg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Gottingen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Greifswald
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Hannover
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Mainz
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Muenchen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Ulm
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Athens
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
Larissa
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Patras
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Thessaloniki
Query!
Country [47]
0
0
Hong Kong
Query!
State/province [47]
0
0
Hong Kong
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Afula
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Jerusalem
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Petach-Tikva
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Bologna
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Brindisi
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Cagliari
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Cona
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Genova
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Milano
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Napoli
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Orbassano
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Palermo
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Pavia
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Pisa
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Reggio Calabria
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Roma
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Sassari
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Seoul
Query!
Country [66]
0
0
Lebanon
Query!
State/province [66]
0
0
Hazmiyeh
Query!
Country [67]
0
0
Malaysia
Query!
State/province [67]
0
0
Kota Bahru
Query!
Country [68]
0
0
Malaysia
Query!
State/province [68]
0
0
Kuala Lumpur
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Nijmegen
Query!
Country [70]
0
0
South Africa
Query!
State/province [70]
0
0
Johannesburg
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Parktown
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Baracaldo
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Barcelona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Sevilla
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Valencia
Query!
Country [77]
0
0
Switzerland
Query!
State/province [77]
0
0
Geneve
Query!
Country [78]
0
0
Switzerland
Query!
State/province [78]
0
0
Zurich
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Taichung
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Taipei
Query!
Country [81]
0
0
Thailand
Query!
State/province [81]
0
0
Bangkok
Query!
Country [82]
0
0
Thailand
Query!
State/province [82]
0
0
Chaingmai
Query!
Country [83]
0
0
Turkey
Query!
State/province [83]
0
0
Adana
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Ankara
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Istanbul
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Izmir
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Leeds
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Leicester
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
London
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Manchester
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00171821
Query!
Trial related presentations / publications
Porter JB, El-Alfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, El-Ali A, Han J, Cappellini MD. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016 Jan;96(1):19-26. doi: 10.1111/ejh.12540. Epub 2015 Jun 23. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, El-Ali A, Habr D, Martin N, Porter JB. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica. 2013 Jul;98(7):1045-8. doi: 10.3324/haematol.2012.077669. Epub 2013 Apr 12. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011 Jan;96(1):48-54. doi: 10.3324/haematol.2010.031468. Epub 2010 Nov 11. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB; EPIC study investigators. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010 Oct 7;116(14):2448-54. doi: 10.1182/blood-2010-01-261289. Epub 2010 Jun 21. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 Mar 25;115(12):2364-71. doi: 10.1182/blood-2009-04-217455. Epub 2009 Dec 8. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00171821
Download to PDF